USPTO Patent Grants - Therapeutics (A61P)

USPTO Patent Grant: Theranostic Agents for PSMA Positive Cancers

The USPTO has granted a patent (US12582728B2) to Memorial Sloan Kettering Cancer Center for theranostic agents targeting PSMA positive cancers. The patent covers compositions and methods for detecting and treating cancer using novel radiohalogenated PSMA targeting agents for diagnostic imaging and radiation therapy.

USPTO Patent Grant: Kit for Producing and Storing Radiopharmaceuticals

The USPTO has granted patent US12582729B2 to Wake Forest University Health Sciences for a kit technology designed for the production and long-term storage of Zr-89-PET radiopharmaceuticals. The patent covers improved stability for radiopharmaceuticals and a method for their production.

USPTO Patent Grant: Diagnostic Antibodies Against MUC17

The USPTO has granted patent US12577322B2 to Amgen Inc. for diagnostic antibodies against mucin 17 (MUC17). These antibodies and associated detection systems are intended for detecting, quantifying, and monitoring MUC17 related to disease diagnosis, progression, and therapeutic response.

USPTO Patent Grant for Bispecific Antibodies

The USPTO has granted a patent (US12577314B2) to ABL BIO INC. for bispecific antibodies designed to treat diseases related to BCMA and/or 4-1BB proteins. The patent covers the antibody's structure and its therapeutic applications.

US Patent 12577313B2 for Bispecific Antibodies

The USPTO has granted US Patent 12577313B2 for bispecific antibodies targeting claudin 18.2 and 4-1BB, assigned to I-Mab Biopharma US Limited. The patent covers novel antibody designs that can trigger tumor-specific immune responses.

Anti-CSF1R Antibodies and Pharmaceutical Compositions Patent

The USPTO has granted patent US12577309B2 for anti-CSF1R antibodies, pharmaceutical compositions, and their uses. The patent was assigned to DRAGONBOAT BIOPHARMACEUTICAL (SHANGHAI) CO., LTD. and lists six inventors. The patent's abstract describes antibodies against human CSF-1R.